Effects of age on treatment in patients with cutaneous melanoma-A multicentre analysis from the ADOREG Registry
U. Leiter-Stöppke(Essen University Hospital), U. Hillen, T. Gambichler, Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Christoffer Gebhardt(Universität Hamburg), Anja Gesierich(University of Michigan), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Sebastian Haferkamp(University Hospital Regensburg), Andrea Forschner(University of Tübingen), Claudia Pfoehler(MSH Medical School Hamburg – University of Applied Sciences and Medical University), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Julia Welzel(University Hospital Augsburg), Elisabeth Livingstone(German Cancer Research Center), Peter J. Mohr(Roche (Switzerland)), Teresa Amaral(University Children's Hospital Tübingen), Selma Ugurel(Klinikum Bielefeld), Frank Meiß(University of Freiburg), Lisa Zimmer(The University of Sydney), Jessica C. Hassel(German Cancer Research Center), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Martin Kaatz(SRH Wald-Klinikum Gera), Imke von Wasielewski(Medizinische Hochschule Hannover), Lena Nanz(University Children's Hospital Tübingen), Patrick Terheyden(University Hospital Schleswig-Holstein), Jens Ulrich, Carola Berking(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k